MAFLD / MASLD - What It Is, How It Progresses, and How It Is Staged
MAFLD, also now commonly discussed under MASLD terminology, is the main reason liver screening demand is rising in Australia. It connects obesity, type 2 diabetes, metabolic syndrome, and liver fibrosis into one of the country’s biggest underdiagnosed chronic disease pathways.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes and pathway literacy. It is not patient-specific medical advice.
- Around 30% of Australian adults are estimated to be living with MAFLD, making it a major primary-care screening target.
- The key clinical challenge is identifying which patients have already progressed from steatosis to clinically significant fibrosis.
- Modern pathways increasingly use FIB-4 first and elastography second when results remain indeterminate.
- MAFLD usually develops quietly and often causes no symptoms until disease is more advanced.
- A diagnosis does not automatically mean cirrhosis, but it does mean the liver should be staged properly and monitored over time.
- Blood tests, scans, and lifestyle changes are all part of the next-step conversation after diagnosis.
What MAFLD means in the Australian setting
The market research used for this project estimates that more than 6 million Australians are living with MAFLD. That makes it a population-scale condition rather than a specialist-only problem.
The biggest risk groups are people with obesity, type 2 diabetes, hypertension, dyslipidaemia, and broader metabolic syndrome. These are exactly the patients most often seen in general practice and community metabolic care.
How the disease progresses
The usual spectrum is steatosis first, then inflammatory liver injury in a subgroup of patients, then fibrosis, cirrhosis, and in some patients hepatocellular carcinoma. The key management question is not whether fat is present alone, but whether fibrosis is already developing.
That is why the playbook repeatedly prioritises advanced fibrosis detection over broad biopsy use. The goal is to find the patients who need closer management, surveillance, or specialist referral before they present late.
Diagnosis and staging
Current pathways increasingly start with simple risk scores such as FIB-4 and then move to elastography when the result is uncertain or when fibrosis needs to be staged more confidently.
Elastography is useful because it offers a non-invasive estimate of fibrosis and, depending on the platform, a steatosis output as well. That makes it a strong fit for MAFLD where repeat monitoring is often more important than one-off biopsy.
Treatment and monitoring
Management still starts with metabolic risk reduction, weight loss, diabetes care, and long-term follow-up. Newer therapies such as resmetirom increase the importance of reliable serial staging because they create more reasons to monitor fibrosis and steatosis over time.
For clinics, this means MAFLD is not just a diagnosis page topic. It is the core volume driver for future elastography demand in Australia.
Related pages
Next steps for clinicians